Novo Nordisk CEO Jorgensen to Leave After Fall in Share Price

Faced with the fall of its stock exchange price due to fierce competition from its American rival Lilly, the Danish laboratory decided to change its managing director.

Novo Nordisk CEO steps down amid obesity drug market setbacks

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant battles intensifying competition in the global obesity drug market. The decision, announced Friday, follows a dramatic 50% drop in the company’s share price since mid-2024. The maker of blockbuster drugs Wegovy and Ozempic cited ongoing market challenges and disappointing trial results for its next-generation treatment Cagr…

Ozempic-Maker CEO Ousted Over Pharma Company's Rocky Market Downturn

Lars Fruergaard Jørgensen is out.

Novo Nordisk announces CEO transition as share price slips

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs.  The Ozempic maker’s chief executive, Lars Fruergaard Jørgensen, first joined the company as an economist in 1991. Jørgensen has served as Novo Nordisk’s CEO since 2017, leading the company before the current gold rush in weight-loss drug development was imaginable.  Novo Nordisk cited market…

The Danish laboratory, pioneer of treatments for diabetes and weight loss, is losing market share.

Ozempic CEO's Exit From Novo Started With Teams Call Surprise

(Bloomberg) — When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge Lund, he was expecting an ordinary catchup.